To evaluate the mechanisms of action of procainamide on the components of the reentrant pathway, drug-induced changes in activation patterns, effective refractory periods (ERPs), and stimulation thresholds were analyzed in nine dogs with sterile pericarditis and sustained atrial flutter. Activation maps were based on 127 close bipolar recordings from a special "jacket" electrode. From the control map, 22±2 sites covering the slow zone and the normal zone of the reentrant circuit were selected to measure ERPs and thresholds. The excitable gap was estimated from the longest ERP during pacing at the tachycardia cycle length. During atrial flutter, epicardial activation proceeded as a single wave around an arc of functional conduction block in the proximity of the atrioventricular (AV) ring or around a combined functional/ anatomic obstacle, with the arc being contiguous with one of the venae cavae. An area of slow conduction, which accounted for 53+15% of the revolution time within 35±15% of the total length of the reentrant pathway, was bordered by the arc of block and the AV ring or a caval vein and the AV ring, respectively. Procainamide (5-10 mg/kg i.v.) prolonged the cycle length of atrial flutter from 144± 17 to 190 ±24 msec (p<0.05) and then terminated the arrhythmia in all studies. The increase in cycle length was due to an increase in conduction time in the slow zone by 37± 11 msec (86±17% of the total cycle length increase). During the last reentrant beat, conduction failed in the slow zone, with the arc of block joining the AV ring. At termination, procainamide had prolonged conduction time, stimulation threshold, and ERP in the normal zone by 11±18%, 40±80%, and 5±15%, respectively, compared with 51±16%, 86±93%, and 14±21%, respectively, in the slow zone (p<0.05 for all three parameters). The duration of the excitable gap did not change significantly. We conclude that procainamide preferentially affected the slow zone of single loop reentrant circuits. The drug terminated circus movement atrial flutter without abolishing the excitable gap, and its effect on conduction seemed the major determinant of the antiarrhythmic action. (Circulation Research 1991;68:1117-1126 In recent years, various canine models of circus movement atrial flutter have been used to evaluate the mechanism of action of antiarrhythmic drugs.1-6 Functional models, which are based on the creation of right atrial enlargement7 or sterile pericarditis,8 seem to closely resemble the clinical situation.9 Previous studies in these functional models2'4 did not consider the pattern of activation before
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We have recently described the epicardial activation patterns during circus movement atrial flutter in the canine sterile pericarditis model.1" Single loop circus movement occurred around functional or combined functional/anatomic obstacles primarily in the right atrium. An area of slow conduction, which was bounded by the central obstacle and the atrioventricular (AV) ring, was an integral part of the reentrant circuit. Spontaneous termination was consistently due to failure of conduction within the area of slow conduction. Entrainment of the arrhythmia at pacing cycles 5-30 msec shorter than the spontaneous cycle length12 indicated the presence of an excitable gap.
The present study was designed to evaluate the mechanisms of action of procainamide on circus movement atrial flutter in the canine sterile pericarditis model. Different from previous studies,1-6 we used mapping techniques to address the following questions: 1) Is the antiarrhythmic action of procainamide associated with a change in the reentrant pathway? 2) Does the drug act differentially on the different components of the reentrant pathway, and is there a preferential site of termination? and 3) How are local changes in conduction, excitability, and refractoriness related to the termination of circus movement reentry in this model?
Materials and Methods

Surgical Procedure and Data Acquisition
Details of the model preparation, the recording techniques, and the methods for constructing isochronal activation maps have been previously described.11,13-15 Sterile pericarditis was created in 14 mongrel dogs (15-20 kg) by generously dusting the epicardial surface of both atria with talcum powder.8 After recovery, induction of atrial flutter by rapid atrial pacing was attempted daily with the dogs in the conscious, nonsedated state. Mapping studies were performed on the day after induction of sustained atrial flutter (3-5 days after the inital surgery). The chest was reopened, and a specially designed electrode array was placed on the epicardial surface of both atria. This atrial "jacket" consisted of a flexible nylon mesh that contained 111 bipolar recording electrodes with an interpolar distance of 1-2 mm. The interelectrode distance ranged from 3 to 5 mm but could reach 5-8 mm in certain areas (e.g., the atrial appendages) when the nylon mesh was stretched. Five small Teflon patches containing two to five electrode pairs provided 16 additional bipolar recordings from the area between the pulmonary veins, below the inferior vena cava and the anterior aspect of the atrial appendages. Data were stored and analyzed with a custom-designed 128-channel computerized multiplexer recording system. Activation times were automatically assigned by the computer system based on the maximum first derivative of the electrogram. Computer determinations were confirmed or corrected after review of each individual recording. Multiphasic electrograms were lined up with the surface ECG and the electrograms at adjacent electrode sites to differentiate local from distant activation. If the remaining portion of the signal was still multiphasic, the peak of the major deflection was chosen as the moment of activation.11'13-15 From these activation times, isochronal epicardial activation maps were manually constructed at 10-msec intervals. During the mapping experiments, ECG leads II, III, and aVF; a left or right atrial electrogram; and aortic blood pressure were continuously monitored on an Electronics for Medicine VR 12 recorder (PPG Biomedical Systems, Lenexa, Kan.).
Study Protocol
After placement of the jacket electrode, several spontaneous beats were recorded to confirm a normal sinus activation. Induction of atrial flutter was then attempted either by rapid burst pacing or by critically timed premature stimuli, which were produced by a Bloom DTU-101 digital stimulator (Bloom Associates, Ltd., Reading, Pa.). Once sustained atrial flutter was induced, recordings from all 127 electrode sites were obtained and used to construct an epicardial activation map (control map). Cycle length and ECG morphology of the induced atrial flutter were observed for at least 30 minutes to document the stability of the arrhythmia. In five dogs with sustained atrial flutter, a 10% solution of procainamide by hydrochloride (Baxter Healthcare Corp., Deerfield, Ill.) at a dose of 5 mg/kg i.v. was then administered over a period of 2 minutes. This injection was repeated if the drug did not terminate the atrial flutter within 3 minutes after its administration. ECG leads II, III, aVF, and epicardial electrograms from all 127 sites were continuously recorded until the arrhythmia was terminated.
In four separate dogs with sustained atrial flutter, the control arrhythmia was interrupted after 30 minutes by rapid burst pacing. On the basis of the control map, 20-24 (22+2) electrode sites covering the slow and normal zones of the reentrant circuit were chosen to measure local stimulation thresholds and refractory periods (see next section below). Atrial flutter was then reinduced and observed for 15 minutes. The epicardial activation sequence of the reinduced arrhythmia was determined and compared with the control map to assure the consistency of the reentrant circuit. Procainamide (5 mg/kg) was then administered according to the above protocol. On termination of the arrhythmias, electrophysiological measurements were repeated at all selected electrode sites. During these measurements, care was taken to alternate between sites covering the slow and normal zones of the reentrant circuit.
Blood samples for procainamide plasma level determinations were drawn immediately after termination of the arrhythmia.
Electrophysiological Measurements
The surface ECG and the accompanying atrial electrogram were used to determine both the atrial and ventricular cycle lengths during atrial flutter before and after the administration of procainamide. In case of an irregular atrioventricular relation, an average ventricular cycle length was calculated from five consecutive cycles. For either parameter, measurements of procainamide effects were obtained during the last five cycles before termination.
Epicardial activation maps during several consecutive cycles of the control arrhythmia (totaling at least 1 second) and during the last three to five cycles after the administration of procainamide were constructed. The length of the central obstacle around which the reentrant wave front circulated was determined as follows: The number of electrode sites an arc of functional conduction block spanned was used to determine its length based on an average interelectrode distance of 5 mm. The diameter of the caval veins was approximated with 10 mm, so that their circumference was calculated at about 30 mm (circumference= 7r-x diameter). The size of the central obstacle determined the length of the reentrant pathway (circumference of the anatomic obstacle [if involved] and length of the functional arc of blockx2). The slow zone of the reentrant circuit was arbitrarily defined as an area of crowded isochrones enclosed between the central obstacle and the AV ring. On the basis of the control map, two electrode sites at the entrance and exit of the slow zone were chosen as reference sites. The spatial distance and the difference in activation time between the two reference electrodes determined the length and conduction time of the slow zone, respectively. With these parameters, the relative contribution of the length of the slow zone to the total length of the reentrant pathway, the conduction velocity within the slow zone, the conduction velocity in the normal zone, and the average conduction velocity of the circulating wave front could be calculated. A representative example is shown in Figure 1 . In this and all subsequent figures, a posterior view of the epicardial atrial surface is displayed in a planar projection. The atria are separated from the ventricles along the AV ring. The inferior bodies of the atrial appendages are incised from the AV ring to their tips and unfolded. Heavy black dots indicate the position of the 127 bipolar recording electrodes. A single reentrant loop was oriented around a combined functional/anatomic obstacle that included the circumference of the superior vena cava and a long arc of functional conduction block. The functional arc of block spanned about seven electrode pairs (approximately 35 mm). This phenomenon, together with the circumference of the superior vena cava, resulted in a reentrant path length of about 100 mm. The area between electrode sites A and B, which were about 20 mm apart from each other, was considered to represent the slow zone of the reentrant circuit. Thus, the slow zone accounted for 20% of the total length of the reentrant pathway. Conduction from sites A to B took 70 msec, or 47% of the revolution time within the circuit (150 msec), translating in an apparent conduction velocity16 of 0.29 m/sec. In contrast, the apparent conduction velocity in the normal zone of the circuit was 1 m/sec, and the average conduction velocity of the circulating wave front was 0.67 m/sec. Because of the uncertainty of the conduction path on a microscopic level,16 respective data were used for descriptive purposes only. To quantify the effect of procainamide on the components of the reentrant pathway, only conduction times between the reference sites before and after application of the drug were compared.
In four dogs, the stimulation threshold at 20-24 selected sites was determined during monopolar cathodal stimulation at a basic cycle length of 250 msec. A current of two times diastolic threshold strength and a train of eight basic beats at a cycle length of 250 msec was then used to determine the effective refrac- tory period (ERP) at these sites. The ERP was defined as the maximum coupling interval of a premature stimulus that failed to evoke a propagated atrial response To avoid recruitment of less refractory tissue at some distance from the stimulating electrode, only sites requiring less than 10 mA for threshold stimulation were included in the control measurements. For statistical analysis of the effect of procainamide on the threshold of excitability, a value of 10 mA was taken as the threshold for procainamide if the drug increased a previously lower threshold beyond this value. Thus, our data tend to underestimate the actual effect of procainamide on the threshold of excitability. The ERP for procainamide at sites requiring a threshold current above 10 mA was not determined.
To allow an estimate of the excitable gap, even after termination of the arrhythmia, we also determined the longest ERP within the circuit at a paced cycle length identical to the tachycardia cycle length before and after the administration of procainamide. The difference between this measure of ERP and the cycle length of the flutter constituted the excitable gap under each condition.6
Statistical Methods
Data are expressed as mean+SD. Basic comparative statistics were performed with Student's t test for paired or unpaired data when appropriate. A confidence level of 95% was considered statistically significant.
Results
In the open-chest state, nine of the 14 dogs (64%) with sterile pericarditis had inducible sustained atrial flutter and could be included in the drug studies.
Control Reentrant Circuits
In all nine dogs with sustained atrial flutter, the arrhythmia could be repeatedly induced. Cycle length and epicardial activation sequence were consistent during subsequent episodes in the same dog. Sustained atrial flutter was always due to a single loop circus movement around merely functional (n = 4) or combined functional/anatomic (n = 5) obstacles in the right (n=8) or left (n=1) atrium. An area of slow conduction was an integral part of all reentrant circuits. The slow zone was bounded by the central obstacle and the nearby AV ring and accounted for 53+15% of the revolution time within 35 + 15% of the total length of the reentrant pathway. Functional and geometric properties of the nine control reentrant circuits and their components are summarized in Table 1 .
Effects of Procainamide on the Epicardial Activation Pattem
Procainamide at an average dose of 7.2±5.1 mg/kg terminated the arrhythmia in all nine dogs. The drug plasma level at the time of arrhythmia termination was 7.2±4.4 ,ug/ml. The effects of procainamide on the epicardial activation pattern were consistent in all experiments and are illustrated by a representative example in In this dog, the control arrhythmia was due to a single circulating wave front around an arc of functional conduction block that ran parallel to the AV ring in the lower right atrium (Figure 2A ). An area of slow conduction was enclosed between the AV ring and the arc of block. The location of electrode sites I and A represented the entrance and the exit of the slow zone, respectively. Selected electrograms (Figure 2B) showed a multiphasic, broad configuration in the area of slow conduction (sites J, K, and L), and electrodes I and A recorded relatively sharp, biphasic deflections. Two minutes after the application of procainamide, the spread of activation was nearly unchanged ( Figure 3A) , although the tachycardia cycle length had increased from 180 to 200 msec. This increase was due to further slowing of conduction in the slow zone of the circuit, so that electrode sites I and A were now separated by 11 isochrones. The multiphasic signals in the slow zone (electrograms J, K, and L in Figure 3B ) seemed to reflect these changes by an increase in electrogram duration. After 3 minutes, the cycle length had increased to about 220 msec. Again, the epicardial activation pattern was nearly unchanged ( Figure 4A ). However, electrode sites I and A were now separated by 13 isochrones. During the last cycle ( Figure 4B ), conduction failed near the exit of the slow zone between electrode sites B and A. The increase in conduction time in the area of slow conduction was accompanied by an increase in electrogram duration ( Figure 5 ). The activation sequence remained stable during the last four beats, and no oscillations or changes in cycle length were evident before termination.
Progressive slowing of conduction and eventual conduction failure in the slow zone of the circuit without significant changes in the overall activation pattern were the typical findings during drug-induced termination of circus movement atrial flutter.
Effects of Procainamide on Conduction: Quantitative Analysis
At termination, procainamide had prolonged the atrial flutter cycle length by 32±16%. At the same time, the ventricular cycle length did not change significantly (-0.9±21%). The conduction time in the slow zone had increased by 54±32% and now accounted for 60±13% of the flutter cycle. In contrast, procainamide had no significant effect on the conduction time in the normal zone. Thus, 86±17% of the increase in atrial flutter cycle length was attributed to the increase in conduction time in the slow zone of the circuit. Data sustained atrial flutter. In all four experiments, a are summarized in Table 2 . single dose of procainamide (5 mg/kg) was sufficient to terminate the arrhythmia. At termination, the Effects of Procainamide on the Threshold of drug had prolonged the cycle length of the flutter by Excitability, the Effective Refractory Period, and the 30±13%. The control values for both the threshold Duration of the Excitable Gap of excitability (4.8±2.2 versus 3.0+2.1 mA) and the The data listed in Table 3 
Effects of Procainamide on the Components of the
Reentrant Pathway: Comparative Analysis Figure 6 compares the relative increase (procainamide versus control) in conduction time, threshold of excitability, and ERP for the slow and normal zones of the four reentrant circuits that provided the data in Table 3 . For all three electrophysiological parameters, the effect of procainamide was more pronounced in the area of slow conduction, with the threshold of excitability showing the most dramatic increase.
Discussion
We found that the pharmacological conversion of circus movement atrial flutter in this functional model of reentry did not involve a change in the geometry of the reentrant pathway at the spatial resolution of our electrode array. The electrophysiological properties in the reentrant pathway were inhomogeneous, as indicated by the spatial differ- ences in conduction, threshold of excitability, and refractoriness. Procainamide acted preferentially on the slow zone of the reentrant circuit, where further slowing and eventual failure of conduction resulted in termination of the circus movement. Lengthening of atrial refractoriness is apparently not a major determinant of the antiarrhythmic effect, because changes in ERP at were relatively small and the drug terminated the arrhythmia without abolishing the excitable gap.
Methodological Considerations
Circus movement atrial flutter in the canine sterile pericarditis model seems to closely resemble its clinical counterpart.9 The inflammatory reaction creates the pathophysiological substrate for the arrhythmia; thus, findings on the mechanisms of action of antiarrhythmic drugs in this model might be applicable to atrial flutter in the diseased human atrium. However, our findings do not necessarily apply to classical atrial flutter in general. The induced arrhythmia is reproducible and stable,8 with a consistent reentrant activation pattern from episode to episode.1" The impulse circulates around a functional or combined functional/anatomic barrier. During atrial flutter the rhythm can be entrained, and an excitable gap is present.1217 As demonstrated by this and our previous study,'1 the electrophysiological properties in the reentrant pathway vary considerably. An area of slow conduction is an integral part of the reentrant circuit. In preparations like this, it is not clear what druginduced changes in the average conduction velocity or the ERP at randomly selected sites might mean and how these changes would be related to the antiarrhythmic action of the drug.6 Thus, local changes in conduction and refractoriness at electrode sites known to be located in the reentrant circuit must be considered. This requirement emphasizes the need for a detailed analysis of the reentrant activation pattern.
The mapping technique used in the present study allows simultaneous recordings from 127 epicardial atrial sites in the in situ canine heart. The disadvantage of this in vivo approach is the inability to record from the interatrial septum. However, it seems that at least the major portion and the crucial components of the reentrant circuits in the canine sterile pericarditis model are located in the atrial free wall. 11 The atrial septal tissue, which is not involved in the inflammatory reaction, is not likely to exhibit slow conduction or conduction block. The epicardial fat does not permit electrical recordings from the area adjacent to the tricuspid annulus. However, slow conduction or conduction block close to the AV ring, as noted with our recording technique, was always associated with respective changes in the reentrant activation pattern. If the conduction pattern in the small rim of tissue not accessible to our recording technique had been different, conduction through this isthmus would have short-circuited slow conduction or conduction block.
Obviously, any mapping technique is ultimately limited by the spatial resolution it provides, so that measurements at any given spatial level might still not accurately reflect the situation at an even smaller scale. Although this inherent limitation is less important when comparing the electrophysiological properties and the susceptibility to pharmacological interventions of the slow and normal zones of the reentrant circuit, it must be considered for the interpretation of our data on the duration of the excitable gap. However, at tachycardia termination, the longest ERP determined during atrial pacing at the tachycardia cycle length was 48+±18 msec shorter than the tachycardia cycle length. Because the duration of all ERPs measured in the slow zone fell into relatively narrow range (18+3 msec), it seems unlikely that at a higher spatial resolution we would have found an ERP value that approached or exceeded the tachycardia cycle length at termination.
In defining the geometric and functional properties of the slow zone, we encountered two major problems. Because of the uncertainty of the conduction path on a microscopic level,16 the calculation of conduction velocities based on the apparent macroscopic path length is of limited relevance. Thus, only drug-induced changes in conduction time between two reference sites were evaluated. The selection of these reference sites necessarily introduced a certain inaccuracy because the transition between normal and slow conduction seemed continuous. Therefore, although the area defined as the slow zone could have included minor portions of the normal zone and vice versa, this possibility would not have affected the principal findings of our study. In fact, an even more marked difference in the effect of procainamide on the slow zone and the normal zone probably could have been shown had a more accurate distinction between the two components of the reentrant pathway been possible.
Measurements of the duration of the excitable gap in an experimental setting designed to evaluate the mechanisms of drug-induced termination of reentrant arrhythmias create several difficulties. 6 The shortest coupling interval of a premature stimulus able to reset a sustained circus movement probably provides the most accurate estimate, although this measure is obviously not independent of the site of stimulation. Although control measurements could easily apply this method, the situation is quite different after application of an antiarrhythmic drug. It is not possible to anticipate the moment of tachycardia termination, and repeated measurements during the sustained rhythm are likely to terminate the arrhythmia. After pharmacological conversion, the tachycardia is not always reinducible, and reinduced arrhythmias do not necessarily use the same reentrant pathway.
We used the difference between the tachycardia cycle length and the longest ERP during atrial pacing at the tachycardia cycle length to derive an estimate of the duration of the excitable gap that could be determined with the same method under both control conditions and after the administration of procainamide. The validity of this measurement is based on the assumptions that the excitable gap of a reentrant circuit is governed by the site with the longest ERP and that the selected electrode sites represented the spatial distribution of refractoriness with reasonable accuracy. Our previous observations on entrainment of atrial flutter in the canine sterile pericarditis model12 support these assumptions. Atrial flutter could be entrained to a stimulated cycle length 5-30 msec shorter than the cycle length of the spontaneous arrhythmia, which would be comparable to the duration of the excitable gap in the present study.
Comparison With Previous Studies
Experimental studies on the mechanism of action of antiarrhythmic drugs on circus movement atrial flutter have used anatomicl3,5,6 or functional2,4 models of atrial reentry. In anatomic models the reentrant pathway is predetermined, and the circulating wavefront encounters only normal atrial tissue. The electrophysiological properties in the reentrant pathway are uniform, and there is no indication of a preferential site for tachycardia termination.'8 Although the data obtained from these models are more susceptible to simple interpretation,6 their relevance to the clinical situation is uncertain. In functional models the electrophysiological properties in the reentrant pathway are nonuniform, with the tissue being more or less affected by the underlying pathology. Although the cellular basis for these nonuniformities awaits further study, antiarrhythmic drugs are not expected to exert uniform effects on respective areas. The circuit path is only functionally determined and might be subject to drug-induced alterations. Previous studies in functional models of circus movement atrial flutter2,4 have measured the effect of antiarrhythmic drugs on the tachycardia cycle length and electrophysiological parameters at randomly selected sites. Our study has clearly demonstrated that not only the control values for conduction times, ERPs, and stimulation thresholds but also the effect of procainamide on these parameters vary considerably in the reentrant pathway. Thus, a change in conduction time or ERP at a site uncritical to the reentrant circuit or a change in the average conduction time is of little relevance in assessing the mechanism of action of antiarrhythmic drugs.
In the present study, a relatively small dose of procainamide (5 mg/kg) was usually sufficient to terminate the arrhythmia. In contrast, Wu and Hoffmnan3 reported that 16-32 mg/kg procainamide were required to terminate circus movement atrial flutter around an anatomic barrier in the otherwise normal canine atrium. In our study, the fact that the reentrant pathway contained functionally abnormal atrial tissue might account for this difference. The smaller doses of procainamide could also explain why the observed changes in refractoriness, even in the normal zone, were not as pronounced as in other studies.3'19
Electrophysiological Basis for the Pharmacological Conversion of Circus Movement Atrial Flutter
Early studies on arrhythmias caused by circus movement recognized that reentry was possible only if the length of the circus path exceeded the wavelength of the impulse.20'21 Lewis22 subsequently postulated that an antiarrhythmic drug would terminate circus movement only if it prolonged refractoriness more than it slowed conduction, so that the wavelength of refractoriness exceeded the path length. The wavelength of the cardiac impulse was mathematically formulated by Wiener and Rosenblueth23 as the distance the depolarization wave traveled during the duration of the refractory period (wavelength equals conduction velocity times refractory period). Recent studies24,25 have revived interest in the wavelength of refractoriness relative to the initiation and persistence of reentrant atrial arrhythmias and also have suggested that the wavelength of refractoriness might be a useful parameter for evaluating antiarrhythmic drugs. These concepts were developed on the basis of the leading circle model of reentry,26 where the leading edge of the impulse arises immediately after the end of the ERP and no excitable gap is present. Wu and Hoffman3 and Spinelli and Hoffman6 studied the effect of antiarrhythmic drugs on atrial reentry around an anatomic barrier with a partially excitable gap. They found that the observed changes in the wavelength of refractoriness in their model did not explain the manner by which these agents brought about the termination of the reentrant excitation. The present study was conducted in a model of reentrant atrial flutter in which the circus movement is oriented around a functional or functional/anatomic barrier and has an excitable gap.1"12'17 In this functional model of reentry with markedly nonuniform electrophysiological properties in the reentrant pathway, the mean spatial value of the wavelength of refractoriness is obviously of little value. If the atrial refractoriness was a major determinant of the pharmacological conversion of circus movement atrial flutter, then the local wavelength at the site with the longest ERP should have exceeded the path length of the last reentrant impulse. (The ERP at that site should have exceeded the duration of the last reentrant cycle.) In our study, the effects of procainamide on the refractoriness throughout the reentrant pathway were relatively modest, and the drug always terminated the arrhythmia without abolishing the excitable gap. In fact, procainamide slowed conduction in the slow zone of the reentrant circuit more than it prolonged refractoriness. Termination of circus movement atrial flutter was typically preceded by a large increase in cycle length, which predominantly resulted from further slowing of conduction in the slow zone. This increase in conduction time was accompanied by a marked increase in the threshold of excitability and by broadening and slurring of the electrograms in the area of slow conduction. These findings provide evidence that supports the hypothesis that procainamide interrupted circus movement reentry by depressing conduction in the slow zone to a point at which propagation of the impulse became impossible. A similar mechanism was suggested by Moe27 and Spinelli and Hoffman6 based on experiments with other class I antiarrhythmic agents.
Presently, the electrophysiological basis for slow conduction and conduction block in the sterile pericarditis model is not well defined. Abnormalities in conduction have been attributed to both abnormal cell membrane properties and anisotropic discontinuous propagation.28 If abnormal cell membrane properties are involved, the preferential effect of procainamide on the slow zone of the reentrant circuit might be explained by the cellular electrophysiology because class I antiarrhythmic agents depress conduction more markedly in depolarized fibers. 29, 30 Conversely, modifications of sodium conductance selectively produce dissociated longitudinal conduction in nonuniform anisotropic bundles.3'
